Clinical trial
Gefitinib and Sirolimus in Treating Patients With Recurrent or Refractory Stage…
NCT00098462 · Jonsson Comprehensive Cancer Center, Other · Withdrawn
Key facts
| NCT number | NCT00098462 |
|---|---|
| Title | Gefitinib and Sirolimus in Treating Patients With Recurrent or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer |
| Official title | A Phase I/II Trial of ZD1839 (Iressa®) and Rapamycin (Rapamune) in Patients With Advanced Non Small Cell Lung Cancer |
| Lead sponsor | Jonsson Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Withdrawn |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | gefitinib, sirolimus |
| Enrollment | 0 |
| Start date | Oct 1, 2004 |
| First posted | Dec 8, 2004 |
| Last update posted | Oct 4, 2012 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: